两种阿司匹林剂量预防双胎妊娠子痫前期的比较:一项倾向性评分匹配的多中心回顾性研究
这项国际多中心回顾性队列研究纳入1907例双胎妊娠,比较无阿司匹林、每日80至100 mg及每日160 mg阿司匹林对子痫前期和妊娠期高血压疾病(HDP)的预防效果。倾向性评分匹配后,160 mg组子痫前期风险比为0.63、HDP风险比为0.56,而80至100 mg组风险比未降至1以下;高剂量组未观察到出血或血小板减少等并发症显著增加。作者认为160 mg阿司匹林可能提供更优结局,需进一步研究长期影响并优化剂量策略。
要点
- 双胎妊娠每日160 mg阿司匹林与子痫前期风险比0.63、HDP风险比0.56相关。
- 每日80至100 mg阿司匹林组子痫前期和HDP风险比均未降至1以下。
- 160 mg组未观察到出血或血小板减少等阿司匹林相关并发症显著增加。
核心结论
- 双胎妊娠使用160 mg阿司匹林预防妊娠期高血压疾病可能提供更优结局,与80至100 mg剂量相比并发症无明显增加。
研究设计与样本
- 国际多中心回顾性队列研究,在3个欧洲中心开展,纳入1907例孕13周时有两个活胎的双胎妊娠。
- 排除胎儿畸形、双胎输血综合征、双胎贫血-红细胞增多序列征、双胎反向动脉灌注序列征、孕13周前减胎为单胎及失访者。
- 按阿司匹林使用分为无阿司匹林组1423例(74.62%)、每日80至100 mg组212例(11.12%)和每日160 mg组272例(14.26%)。
- 采用倾向性评分匹配和多因素分析,匹配后对每个结局行Cox回归模型比较三组,P值<.05为有统计学意义。
主要发现
- 倾向性评分匹配母亲年龄、体质指数、种族、产次、子痫前期史、慢性高血压、糖尿病、血栓形成倾向、自然受孕及双胎类型后,三组除年龄和血栓形成倾向(绝对标准化差分别为22.1%和16.4%)外均衡良好(绝对标准化差<15%)。
- 160 mg阿司匹林组子痫前期风险比0.63,HDP风险比0.56。
- 80至100 mg阿司匹林组子痫前期和HDP的风险比均未降至1以下。
- 160 mg阿司匹林组子痫前期<34周风险降低。
- 较高剂量阿司匹林未观察到出血或血小板减少等阿司匹林相关并发症或其他产科结局显著增加。
临床怎么用
- 原文结论未据此给出推荐,仅指出160 mg阿司匹林预防双胎妊娠妊娠期高血压疾病可能提供更优结局。
局限性
- 原文指出需进一步研究探索长期影响并优化双胎妊娠的剂量策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin has proved its efficacy in reducing the rate of preeclampsia in singleton pregnancy; however, there is discrepancy about the efficient dosage that should be used. While some societies recommend daily 75 to 81 mg, others recommend higher dosage (160 mg). This discrepancy is due to the lack of randomized controlled studies that compare these 2 dosages. Moreover, there remains a considerable gap in our knowledge concerning the appropriate prophylactic aspirin dosage for twin pregnancies. OBJECTIVE: This study aimed to assess the efficacy of various aspirin prophylaxis dosages in the prevention of preeclampsia and hypertensive disorders of pregnancy (HDP) in twin pregnancies. STUDY DESIGN: This was an international multicentre retrospective cohort study that was conducted in 3 European centers. We included all twin pregnancies with 2 live fetuses at 13 weeks of gestation (WG). We excluded fetal malformations, twin-twin transfusion syndrome, twin anemia polycythemia sequence, twin reversed arterial perfusion sequence, twin pregnancies at onset but continued as singletons (vanishing twin/arrest before 13 WG), and loss of follow-up. Patients were categorized into 3 groups: no aspirin, daily 80 to 100 mg aspirin, and daily 160 mg aspirin. Primary outcomes were the incidence of preeclampsia and HDP, whereas secondary outcomes were small-for-gestational age, postpartum hemorrhage >1000 mL, antenatal bleeding of obstetrical origin, thrombocytopenia, miscarriage, intrauterine fetal demise, neonatal death, and gastritis. Propensity score matching and multivariate analyses were conducted to assess outcomes including pre-eclampsia, gestational hypertension, maternal complications, and gastritis. Propensity score matching was used to balance the 3 groups of study. Cox regression models were done for each outcome after matching to compare the 3 groups. A P-value<.05 was considered statistically significant. RESULTS: A total of 1907 twin pregnancies were included: 1423 (74.62%) received no aspirin, 212 (11.12%) received 80 to 100 mg, and 272 (14.26%) received 160 mg. After using propensity score matching for maternal age, body mass index, race, parity, history of preeclampsia, chronic hypertension, diabetes mellitus, thrombophilia, spontaneous conception, and type of twin pregnancy, the 3 groups were adequately balanced (absolute standardized difference [ASD] <15%), except for age and thrombophilia (ASD 22.1% and 16.4%, respectively). The administration of aspirin 160 mg decreased the hazard ratio (HR) for preeclampsia to 0.63 and for HDP to 0.56, whereas the administration of aspirin 80 to 100 mg failed to decrease both HR below 1. In addition, aspirin 160 mg decreased the risk for preeclampsia <34 WG. No significant increase for aspirin-related complications, such as bleeding or thrombocytopenia, or other obstetrical outcomes was observed with the higher dose of aspirin. CONCLUSION: The use of 160 mg aspirin for the prevention of hypertensive disorders of pregnancy may offer superior outcomes in twin pregnancies, with no discernible rise in complications when compared to aspirin doses ranging from 80 to 100 mg. Further research should explore long-term impacts and refine dosage strategies for optimal outcomes in twin pregnancies.
引用
- Zorzato P, Torcia E, Carlin A, et al. Comparison of two aspirin doses for the prophylaxis of pre-eclampsia in twin pregnancy: a multicenter retrospective study with propensity score matching. Am J Obstet Gynecol. 2025. PMID: 39788361. doi:10.1016/j.ajog.2024.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。